TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8934728
Drug: FEC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC with high-dose infusional 5-fluorouracil (750 mg/m2 per day/days 1 to 5)
Study: 233444
Drug: tiapride 300
Normalized name: tiapride
DrugBank: Tiapride (DB13025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapride 300 mg/day
Study: 30157242
Drug: subtype C
Approvals — FDA: no, EMA: no, PMDA: no
Description: subtype C prophylactic vaccine (DNA prime: ADVAX and MVA boost: TBC-M4)
Study: 26498057
Drug: Testosterone solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone solution 2% (60 mg topical, once daily)
Study: 12088970
Drug: IV Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Fentanyl (12.5 microg administered immediately after spinal anesthesia)
Study: 1844926
Drug: Ad-libitum feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad-libitum feeding by oral route (Group C)
Study: 6499512
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg spiramycin 3-times daily for 3 days
Study: 6499512
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg erythromycin 3-times daily for 5 days
Study: 26853792
Drug: lidocaine gel+isotonic
Normalized name: lidocaine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine gel+isotonic spray
Study: 18373315
Drug: CVVHDF (pre-dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVVHDF (pre-dilution volume of 600 mls/h with a dialysate dose of 1 L)
Study: 7724752
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material concentration of 240 mg of iodine per milliliter
Study: 6356317
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 tablets of 500 mg 4 times daily)
Study: 31062349
Drug: AVP-825 (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-825 (22 mg)
Study: 11826205
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (0.5 mg/kg/d for 3 days)
Study: 11826205
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (0.2 mg/kg/d for 3 days and 0.1 mg/kg/d for 4 days)
Study: 7029149
Drug: Intrapleural BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural BCG treatment
Study: 26800177
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with anodized surfaces (ANO)
Study: 26800177
Drug: Implants treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants treated by acid (AC)
Study: 25304922
Drug: Proactive feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive feeding regimen (PFR), starting with 100 mL/kg/day and gradually increasing to 200 mL/kg/day by day 4.
Study: 25304922
Drug: Standard feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard feeding regimen, starting with 60 mL/kg/day and gradually increasing to 170 mL/kg/day by day 9.
Study: 22436957
Drug: Autologous MSC
Normalized name: AUTOLOGOUS MSC-NTF
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous MSC plus standard-dose CNI
Study: 19505968
Drug: 0.8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml kg(‐1) of contrast material (350 mgI ml(‐1)) injected with a fixed duration of 10 s (Group B)
Study: 16437721
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL of sodium phosphate (NaP) in a split regimen of two 45 mL doses separated by 12 h
Study: 16437721
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of polyethylene glycol (PEG)
Study: 8604274
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/kg/day for 2 weeks
Study: 1720796
Drug: Desferal (desferrioxamine)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferal (desferrioxamine) 0.1 mg/ml to 100 mg/ml
Study: 1720796
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg (H1 antagonist)
Study: 24491642
Drug: Individualized ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individualized ranibizumab treatment (prior ranibizumab)
Study: 24491642
Drug: Individualized ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individualized ranibizumab treatment (prior ranibizumab + laser)
Study: 9524980
Drug: +/- pindolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: +/- pindolol (30 mg, oral dose)
Study: 7640144
Drug: Sodium acid
Normalized name: sodium acid citrate
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium acid pyrophosphate (SAPP) 1.1 g/200 ml
Study: 7494824
Drug: Mannitol 2.264
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 2.264 g/200 ml
Study: 2707251
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) at doses ranging from 1 to 4 g/day for 13-15 months
Study: 73849
Drug: Levodopa with
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa with carbidopa 66 mg/day
Study: 73849
Drug: Levodopa with
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa with benserazide 151 mg/day
Study: 22307212
Drug: Randomized phase
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized phase II trials assessing systemic cancer therapies
Study: 29206944
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist
Study: 15003077
Drug: Paroxetine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine CR (12.5-37.5 mg/day)
Study: 11699398
Drug: Early outpatient
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early outpatient supportive care following induction chemotherapy with cytosine arabinoside and an anthracycline.
Study: 9608962
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam 0.25 mg.kg‐1 plus intramuscular atropine 0.02 mg.kg‐1
Study: 9608962
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline drops
Study: 6769420
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotics)
Study: 4758423
Drug: Practolol 200
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 200 mg by mouth at the beginning and end of each dialysis
Study: 16565634
Drug: Referral care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral care in the VA general internal medicine clinic
Study: 11270907
Drug: Lorazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.5 mg)
Study: 1822833
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg chronic administration
Study: 1822833
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg acute administration
Study: 1822833
Drug: Nisoldipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (5 mg or 10 mg)
Study: 6798765
Drug: Preparation I
Normalized name: Wound Care Preparation Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation I (SH D 356 A) containing 75 micrograms delta 15-d-norgestrel (Gestoden) + 30 micrograms ethinyloestradiol
Study: 6798765
Drug: Preparation II
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation II (SH D 356 B) containing 75 micrograms d-norgestrel + 30 micrograms ethinyloestradiol
Study: 30342467
Drug: Control (sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sufentanil 0.02 μg/kg/h, Group C)
Study: 23537608
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy services
Study: 22820898
Drug: Escitalopram 10-mg
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-mg daily
Study: 15699018
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airways pressure treatment for 6 months
Study: 6805791
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics
Study: 7551301
Drug: 90-microF biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-microF biphasic waveform with endocardial-subcutaneous array lead system
Study: 2123355
Drug: Mackerel supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mackerel supplement (135 g per day for 6 weeks)
Study: 2123355
Drug: Meat (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat (control) paste (135 g per day for 6 weeks)
Study: 7362089
Drug: Terbutaline tablet
Normalized name: terbutaline Oral Tablet
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline tablet (2.5, 3.75, or 5.0 mg depending on weight)
Study: 7362089
Drug: Terbutaline oral
Normalized name: terbutaline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline oral solution (2.5, 3.75, or 5.0 mg depending on weight)
Study: 18991624
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg once daily)
Study: 27865446
Drug: Utrogestan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan 200 mg
Study: 27865446
Drug: Utrogestan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan 100 mg
Study: 1962900
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Kabi 2165, Fragmin)
Study: 1962900
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Kabi 2165, Fragmin) and Conventional low-dose heparin
Study: 29391018
Drug: 8 weekly
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weekly home visits from nursing students
Study: 26804639
Drug: Buprenorphine Buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Buccal Film (BBUP) 75 µg, 300 µg, 1200 µg (single-dose study)
Study: 26804639
Drug: Buprenorphine Buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Buccal Film (BBUP) 60 µg, 120 µg, 180 µg, 240 µg BID (multiple-dose study)
Study: 22723176
Drug: aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (100 μM)
Study: 2140489
Drug: Nicorandil 20
Normalized name: nicorandil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 20 mg
Study: 2140489
Drug: Nicorandil 40
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 40 mg
Study: 6237916
Drug: Nicorandil 60
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 60 mg
Study: 26420334
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg Se-enriched yeast
Study: 26420334
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg Se-enriched yeast
Study: 26420334
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg Se-enriched yeast
Study: 26420334
Drug: Matching placebo-yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo-yeast tablets
Study: 24281461
Drug: Thalidomide, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide, 1.5 to 2.5 mg/kg per day for 8 weeks
Study: 17168490
Drug: Dynastat (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynastat (new selective COX-2 inhibitor)
Study: 17168490
Drug: Profenid (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profenid (conventional nonsteroidal anti-inflammatory drug)
Study: 14531871
Drug: Fragrance-containing solution
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragrance-containing solution (10 p.p.m. for 2 weeks, then 250 p.p.m. for 2 weeks)
Study: 14531871
Drug: Both fragrance-containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both fragrance-containing and placebo solutions
Study: 9124837
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/day for 3 days)
Study: 3045781
Drug: Erythromycin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (40 mg/kg/day for 10 days)
Study: 3479848
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel
Study: 3548368
Drug: Control (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (gel only)
Study: 19169930
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of oxytocin at the onset of the active phase
Study: 16514097
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement therapy (CI therapy)
Study: 9404405
Drug: L-arginine (L-arg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (L-arg, 625 mg/min x 10 min)
Study: 9404405
Drug: Deferoxamine (DFX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (DFX, 50 mg/min x 10 min)
Study: 8371658
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (both L-CHO and S-CHO)
Study: 8371658
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of sweet placebo (CON)
Study: 2904367
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg kg‐1 (single dose)
Study: 2876574
Drug: Vecuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.015 mg kg‐1 followed by 0.085 mg kg‐1 (divided doses)
Study: 2904367
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg kg‐1 (single dose)
Study: 2876574
Drug: Atracurium 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.075 mg kg‐1 followed by 0.425 mg kg‐1 (divided doses)
Study: 30381400
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Denosumab (DNM) subcutaneously on day 0 and 180
Study: 30381400
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Denosumab (DNM)
Study: 23187888
Drug: Standard unlabelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unlabelled dose of zidovudine (300 mg)
Study: 23187888
Drug: Standard unlabelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unlabelled dose of tenofovir (300 mg)
Study: 18690118
Drug: Nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarette (0.6 mg)
Study: 18690118
Drug: Denicotinized cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denicotinized cigarette (0.05 mg)
Study: 12442929
Drug: Intrauterine papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine papaverine (30 mg)
Study: 12442929
Drug: Bupivacaine (0.375%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.375% 30 mL)
Study: 12442929
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (30 mL)
Study: 1657017
Drug: Trazodone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (75 mg orally)
Study: 18486739
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg
Study: 18832432
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg citalopram (CIT)
Study: 12214580
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate dihydrate (Oxis) at doses of 4.5, 18, and 54 microg via Turbuhaler
Study: 12214580
Drug: Salbutamol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol at doses of 200 and 1800 microg via pressurised metered dose inhaler (pMDI)
Study: 9862585
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium hydroxide (4.5 g per g elemental iron ingested)
Study: 2611358
Drug: Co-trimoxazole (CT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (CT; combination of sulphamethoxazole 800 mg and trimethoprim 160 mg, twice daily for 5 days)
Study: 976306
Drug: Flutiorex 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutiorex 20 mg orally
Study: 31673330
Drug: MoodGYM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodGYM plus physical treatments
Study: 31673330
Drug: Physical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical treatments alone
Study: 26597311
Drug: 0.50% (6.5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50% (6.5mg) DHEA daily for 12 weeks
Study: 29392574
Drug: Single 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300-mg dose of droxidopa in the fed state
Study: 29392574
Drug: Single 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300-mg dose of droxidopa in the fasted state
Study: 29392574
Drug: Norepinephrine levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine levels after dose 1 of TID dosing
Study: 26986171
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (3.7, 4.62, and 5.55 GBq)
Study: 23406027
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy
Study: 20594219
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy
Study: 1346337
Drug: Early zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early zidovudine therapy (1500 mg per day)
Study: 8095008
Drug: Early zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early zidovudine therapy
Study: 27885532
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (0.5 g/kg of ideal body weight)
Study: 23067910
Drug: Enhanced depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced depression care intervention (6-month duration, including problem-solving therapy and/or pharmacotherapy)
Study: 17522584
Drug: Bbeta15-42 (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bbeta15-42 (2.4 mg/kg, n = 6)
Study: 17522584
Drug: Random peptide
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random peptide (control; 2.4 mg/kg, n = 6)
Study: 10189324
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil concentrate (55% eicosapentaenoic and docosahexaenoic acids) 6 g/d for 3 months and then 3 g/d for 21 months
Study: 2302950
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus antacids if necessary to maintain gastric pH at greater than or equal to 4
Study: 427041
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment (iron dextran)
Study: 23359782
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (cilostazol, clopidogrel, and aspirin)
Study: 9710394
Drug: 2 microg
Normalized name: Beta 2 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg intrathecal sufentanil in 3 ml preservative-free saline
Study: 9710394
Drug: 3 microg
Normalized name: Calcitriol 3 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microg intrathecal sufentanil in 3 ml preservative-free saline
Study: 9710394
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg intrathecal sufentanil in 3 ml preservative-free saline
Study: 9710394
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg intrathecal sufentanil in 3 ml preservative-free saline
Study: 7989940
Drug: Infusional fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusional fluorouracil (I‐FU) 1.2 g/m2/d, as a 72‐hour infusion in the first and third weeks of radiation.
Study: 7989940
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusions).
Study: 7967
Drug: Sulfentanil (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfentanil (0.05 mg initial dose followed by 0.025 mg repeat injections)
Study: 7967
Drug: Fentanyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.5 mg)
Study: 16887416
Drug: Normal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hospital diet plus 400 mL oral nutritional supplements
Study: 9382540
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration with 5-FU (arm B)
Study: 1590682
Drug: Ceftazidime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (100 mg/kg/day) plus co-trimoxazole (trimethoprim, 8 mg/kg/day; sulfamethoxazole, 40 mg/kg/day)
Study: 1590682
Drug: Chloramphenicol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (100 mg/kg/day) plus doxycycline (4 mg/kg/day) and co-trimoxazole (trimethoprim, 8 mg/kg/day; sulfamethoxazole, 40 mg/kg/day)
Study: 29626074
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy targeting LDL-C <70 mg/dL
Study: 29626074
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy targeting LDL-C 100-120 mg/dL
Study: 11579272
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg/day for 2 weeks)